236 related articles for article (PubMed ID: 8967757)
1. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.
Miller RG; Petajan JH; Bryan WW; Armon C; Barohn RJ; Goodpasture JC; Hoagland RJ; Parry GJ; Ross MA; Stromatt SC
Ann Neurol; 1996 Feb; 39(2):256-60. PubMed ID: 8967757
[TBL] [Abstract][Full Text] [Related]
2. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group.
Neurology; 1996 May; 46(5):1244-9. PubMed ID: 8628460
[TBL] [Abstract][Full Text] [Related]
3. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).
Penn RD; Kroin JS; York MM; Cedarbaum JM
Neurosurgery; 1997 Jan; 40(1):94-9; discussion 99-100. PubMed ID: 8971830
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.
Clin Neuropharmacol; 1995 Dec; 18(6):515-32. PubMed ID: 8681312
[TBL] [Abstract][Full Text] [Related]
6. Trial of celecoxib in amyotrophic lateral sclerosis.
Cudkowicz ME; Shefner JM; Schoenfeld DA; Zhang H; Andreasson KI; Rothstein JD; Drachman DB
Ann Neurol; 2006 Jul; 60(1):22-31. PubMed ID: 16802291
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis.
Miller RG; Bryan WW; Dietz MA; Munsat TL; Petajan JH; Smith SA; Goodpasture JC
Neurology; 1996 Nov; 47(5):1329-31. PubMed ID: 8909453
[TBL] [Abstract][Full Text] [Related]
8. A randomized sequential trial of creatine in amyotrophic lateral sclerosis.
Groeneveld GJ; Veldink JH; van der Tweel I; Kalmijn S; Beijer C; de Visser M; Wokke JH; Franssen H; van den Berg LH
Ann Neurol; 2003 Apr; 53(4):437-45. PubMed ID: 12666111
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: relation to parameters of the acute-phase response. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.
Clin Neuropharmacol; 1995 Dec; 18(6):500-14. PubMed ID: 8681311
[TBL] [Abstract][Full Text] [Related]
10. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
11. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
Meininger V; Asselain B; Guillet P; Leigh PN; Ludolph A; Lacomblez L; Robberecht W;
Neurology; 2006 Jan; 66(1):88-92. PubMed ID: 16401852
[TBL] [Abstract][Full Text] [Related]
12. Phase II/III randomized trial of TCH346 in patients with ALS.
Miller R; Bradley W; Cudkowicz M; Hubble J; Meininger V; Mitsumoto H; Moore D; Pohlmann H; Sauer D; Silani V; Strong M; Swash M; Vernotica E;
Neurology; 2007 Aug; 69(8):776-84. PubMed ID: 17709710
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Meininger V; Drory VE; Leigh PN; Ludolph A; Robberecht W; Silani V
Amyotroph Lateral Scler; 2009; 10(5-6):378-83. PubMed ID: 19922128
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.
Lauria G; Campanella A; Filippini G; Martini A; Penza P; Maggi L; Antozzi C; Ciano C; Beretta P; Caldiroli D; Ghelma F; Ferrara G; Ghezzi P; Mantegazza R
Amyotroph Lateral Scler; 2009; 10(5-6):410-5. PubMed ID: 19922132
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.
Meininger V; Bensimon G; Bradley WR; Brooks B; Douillet P; Eisen AA; Lacomblez L; Leigh PN; Robberecht W
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Jun; 5(2):107-17. PubMed ID: 15204012
[TBL] [Abstract][Full Text] [Related]
18. [Neurotrophic factor treatment in amyotrophic lateral sclerosis].
Tsuzaka K; Mitsumoto H
No To Shinkei; 1998 Jul; 50(7):625-30. PubMed ID: 9739520
[No Abstract] [Full Text] [Related]
19. Long-term safety of riluzole in amyotrophic lateral sclerosis.
Lacomblez L; Bensimon G; Leigh PN; Debove C; Bejuit R; Truffinet P; Meininger V;
Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):23-9. PubMed ID: 12061945
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
